Apply to trial NCT07048457

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Procedure

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab vedotin-based systemic therapy and surgically resectable or previously radiated metastatic sites.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening